Bifidobacterium longum R0175 Protects Rats against d-Galactosamine-Induced Acute Liver Failure.

Acute liver failure is a severe liver disorder that poses considerable global challenges. Previous studies on R0175 have mainly focused on its psychotropic functions. The current research focused on the protective efficacy of R0175 against acute liver failure caused by d-galactosamine (d-GalN) in rats and further tested the hypothesis that R0175 exerted liver-protective effects by affecting the intestinal microbiota and fecal metabolites and by inhibiting inflammation. We found that oral gavage of R0175 markedly reduced the severity of liver injury in d-GalN-treated rats, as evidenced by decreased serum levels of aspartate aminotransferase (AST) and total bile acids (TBAs) ( < 0.05). Moreover, the plasma concentrations of proinflammatory cytokines (interleukin 1β [IL-1β] and tumor necrosis factor-α [TNF-α]) and chemokines (granulocyte-macrophage colony-stimulating factor [GM-CSF], macrophage chemoattractant protein 1 [MCP-1], chemokine [C-X-C motif] ligand 1 [CXCL1], chemokine [C-C motif] ligand 5 [CCL5], and macrophage inflammatory protein-1α [MIP-1α]) were also markedly reduced ( < 0.05). Pretreatment with R0175 partially reversed the gut microbiota dysbiosis in rats with liver injury by increasing the relative abundances of potentially beneficial bacteria, such as spp., and decreasing the relative abundances of potentially harmful bacteria, such as , spp., and spp. Furthermore, R0175 administration partially improved the metabolic function of the intestinal microbes, as indicated by the decreased level of lithocholic acid found in the feces. Our research investigated the protective and preventive roles of R0175 in a rat model of acute liver failure. The results illustrated that this probiotic strain exhibited protective effects in rats with acute liver failure. Thus, R0175 showed clinical application prospects that required further exploration.